Veerhealth Care (NIYATILEAS) — concall transcript

📢 Key Event
Veerhealth Care targets INR42 crores revenue and INR6 crores EBITDA by FY25, with US exports reaching INR25-30 crores annually by next year.

🔄 What Changed
EBITDA margin improved to 13.70% and export contribution rose to 30% of business compared to previous period, reflecting stronger international demand and contract manufacturing growth.

🔮 What's Next
US export revenue target of INR12-15 crores for current fiscal and INR25-30 crores annually next year, with brand revenue contribution targeted at 35% and total revenue of INR42 crores by FY25.

💡 Investor Takeaway
The company is aggressively expanding its US market presence with existing FDA registration accelerating customer acquisition, positioning it to capitalize on shifting supply chains from China.

Veerhealth Care reported FY24 revenue of INR1,461.29 lakhs with EBITDA margin at 13.70%, driven by 30% export contribution and 55% contract manufacturing. Management targets INR42 crores revenue and INR6 crores EBITDA by FY25, with US exports projected at INR12-15 crores this year and INR25-30 crores annually next year. New capacity expansion plans include a facility under evaluation for oral and body care, while brand revenue aims to grow from 15% to 35% of total. The company is USFDA registered, targeting six major US clients amid China supply chain shifts, with rights issue update expected within four weeks.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NIYATILEAS ✨ Ask AI About This

About Veerhealth Care Ltd (NIYATILEAS)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹98.65 Cr P/E: 64.9 ROE: 6.9% ROCE: 11.2%

View full NIYATILEAS stock details →

📡 Get AI alerts when NIYATILEAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NIYATILEAS — Free

💡 Ask AI about this filing

"What is the timeline for the new manufacturing facility's completion?" "How will the rights issue funds specifically be allocated to expansion projects?" "What is the current utilization rate of the Vapi plant and capacity expansion plans?"

Ask AI Free →

📊 More NIYATILEAS filings

See all NIYATILEAS filings →

🔥 Also filed on 31 March 2024

M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript ULTRACEMCO UltraTech Cement Ltd concall transcript TITAN Titan Company Ltd concall transcript ETERNAL Eternal Ltd concall transcript BEL Bharat Electronics Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NIYATILEAS files new disclosures

Track NIYATILEAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NIYATILEAS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd